SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...

USA: Researchers have found in a new study that patients with psoriatic arthritis (PsA) were more likely to achieve minimal ...

A new nanoparticle drug has shown preclinical promise in both preventing rheumatoid arthritis and reducing painful flare-ups, offering hope for a targeted, steroid-sparing treatment that calms the ...

Biosimilar DMARDs offer cost-effective and improved outcomes over leflunomide for RA patients unresponsive to methotrexate. The study used a Markov model with data from 25,099 RA patients to simulate ...

Patients who require biologic disease-modifying antirheumatic drugs (DMARDs) for severe RA are less likely to achieve sustained DMARD-free remission than those not needing the medication. Patients ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis who cycled JAK inhibitors after inadequate response had a 38.7% remission ...

The initiation of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), particularly rituximab and abatacept, is associated with an increased risk for incident cancer in ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Racial-ethnic disparities in care quantity and quality have been well documented throughout medicine. This study focused on rheumatoid arthritis patients' use of disease-modifying anti-rheumatic drugs ...

ASAS-PerSpA study finds Japanese patients with axial psoriatic arthritis have lower disease activity and better function than ...